Ritonavir - Generic Drug Details

What are the generic sources for ritonavir and what is the scope of patent protection?

Ritonavir is the generic ingredient in two branded drugs marketed by Abbott, Abbvie, Hikma, Quagen, Amneal, Aurobindo Pharma Ltd, Cipla, and Hetero Labs Ltd Iii, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-one drug master file entries for ritonavir. Eight suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for ritonavir

US Patents:	0
Tradenames:	2
Applicants:	8
NDAs:	12
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	106
Clinical Trials:	1,030
Drug Prices:	Drug price trends for ritonavir
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ritonavir
What excipients (inactive ingredients) are in ritonavir?	ritonavir excipients list
DailyMed Link:	ritonavir at DailyMed

See drug prices for ritonavir

Recent Clinical Trials for ritonavir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Muhimbili University of Health and Allied Sciences	PHASE3
Traws Pharma, Inc.	PHASE2
University of Nairobi	PHASE3

See all ritonavir clinical trials

Generic filers with tentative approvals for RITONAVIR

Applicant	Application No.	Strength	Dosage Form
		100MG	TABLET;ORAL
		50MG	TABLET; ORAL
		25MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ritonavir

Drug Class	Cytochrome P450 3A Inhibitor Protease Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors P-Glycoprotein Inhibitors UDP Glucuronosyltransferases Inducers

Medical Subject Heading (MeSH) Categories for ritonavir

Cytochrome P-450 CYP3A Inhibitors

HIV Protease Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ritonavir

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for RITONAVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NORVIR	Tablets	ritonavir	100 mg	022417	1	2010-12-21

US Patents and Regulatory Information for ritonavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	RITONAVIR	ritonavir	TABLET;ORAL	208890-001	Sep 17, 2018	AB	RX	No	No
Abbott	NORVIR	ritonavir	CAPSULE;ORAL	020680-001	Mar 1, 1996		DISCN	No	No
Aurobindo Pharma Ltd	RITONAVIR	ritonavir	TABLET;ORAL	206614-001	Sep 17, 2018	AB	RX	No	Yes
Cipla	RITONAVIR	ritonavir	TABLET;ORAL	202573-001	Jan 15, 2015	AB	RX	No	No

Expired US Patents for ritonavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NORVIR	ritonavir	CAPSULE;ORAL	020945-001	Jun 29, 1999
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010
Abbvie	NORVIR	ritonavir	CAPSULE;ORAL	020945-001	Jun 29, 1999

EU/EMA Drug Approvals for ritonavir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan S.A.S	Ritonavir Mylan	ritonavir	EMEA/H/C/004549Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).	Authorised	yes	no	no	2017-11-09
AbbVie Deutschland GmbH Co. KG	Norvir	ritonavir	EMEA/H/C/000127Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).	Authorised	no	no	no	1996-08-25

Market Dynamics and Financial Trajectory for Ritonavir

Last updated: February 19, 2026

How does Ritonavir fit within the global pharmaceutical market?

Ritonavir is a protease inhibitor primarily used as part of antiretroviral therapy (ART) for treating HIV/AIDS. Its market relevance hinges on its role in HIV management, its competition with other protease inhibitors, and its lifecycle status—either as a branded or generic product.

The global HIV treatment market was valued at approximately USD 22 billion in 2022, with projections to reach USD 27 billion by 2027. Ritonavir's market share is driven by its inclusion in combination regimens but faces competition from other agents such as darunavir and atazanavir.

Limited standalone Ritonavir sales exist; most formulations are marketed in combination pills, which constrains direct revenue but enhances volume.

Pharmacological and regulatory data influencing market positioning

Ritonavir acts as a pharmacokinetic enhancer or booster, used together with other protease inhibitors to increase their plasma concentrations. It was initially developed by Abbott Laboratories, now part of AbbVie after acquisitions.

In 2022, the FDA approved Ritonavir as a booster with other protease inhibitors; its continued use depends on regulatory status across countries. The drug is off-patent in many regions, with generic versions available in India, China, and parts of Europe, increasing market penetration but compressing prices.

Patent and exclusivity landscape

AbbVie's patent for Ritonavir expired in 2015 in the US, though secondary patents extended exclusivity until 2020 in some jurisdictions. Generic competition has eroded market share significantly, leading to price reductions.

Recent patent litigations or extensions are not documented, suggesting limited protections for Ritonavir alone. Instead, combination regimens that include Ritonavir may have proprietary rights, prolonging market exclusivity for specific formulations.

Market competition and product alternatives

Key competitors include:

• Darunavir (Prezista): Higher barrier to resistance, marketed by Janssen.
• Atazanavir (Reyataz): Lower metabolic side effects.
• Lopinavir/Ritonavir (Kaletra): Combination product with Ritonavir as a booster.

Market share shifts toward newer agents with better safety profiles influence Ritonavir's sales. Also, newer integrase inhibitors like bictegravir and dolutegravir further erode protease inhibitor demand.

Pricing and revenue trends

Ritonavir prices have declined markedly since patent expiry. As a booster, it typically costs USD 50–150 per patient per month depending on regional pricing policies. Volume-driven sales dominate revenues; thus, generic availability impacts profitability.

In 2018, annual sales peaked at approx USD 300 million for branded formulations. By 2022, estimates indicate a decline to below USD 150 million, primarily due to generic competition and substitution by newer drugs.

R&D and pipeline prospects

No significant Ritonavir-specific R&D pipelines are publicly documented. However, research continues into novel booster formulations and combination therapies. Future growth depends on niche applications, cost advantages in low-income markets, or new regulatory approvals.

Regulatory and policy considerations

HIV treatment guidelines from WHO and CDC list Ritonavir-based regimens as standard but favor integrase inhibitor regimens. Many low- and middle-income countries retain Ritonavir-based options due to cost and availability, sustaining some demand.

Regulatory changes promoting bioequivalence and generics threaten continued profitability for branded Ritonavir. Divestment or shift to biosimilars are probable strategies among core manufacturers.

Summary Table: Key Market Data

Parameter	2022 Data	Trends/Notes
Market size (global HIV)	USD 22 billion	Steady growth until 2027
Ritonavir revenue	USD 150 million (est.)	Declining from USD 300 million in 2018
Patent expiry	2015 (US), secondary patents until 2020	Opened market to generics
Key competitors	Darunavir, Atazanavir, Lopinavir/Ritonavir	Market share shifting toward newer agents

Key Takeaways

• Ritonavir's revenue has declined due to generic competition and shifts toward newer antiretrovirals.
• Pricing pressures and patent expiration limit profitability.
• Market share persists mainly in low-income regions where regimens are cost-driven.
• No new Ritonavir-specific innovations are in advanced R&D stages.
• Future growth depends on niche applications, epidemiological factors, and potential new formulations or combinations.

FAQs

1. What factors contributed to Ritonavir's revenue decline?
Patent expiration in key markets and the availability of generics lowered prices and volume, while newer drugs replaced Ritonavir in treatment guidelines.

2. How does generic competition affect Ritonavir's market?
Generics significantly reduce prices, leading to lower profit margins and market share erosion, especially in regions like India and China.

3. Are there new formulations or combinations of Ritonavir in development?
No publicly disclosed major Ritonavir-specific R&D programs are active; focus remains on combination therapies already approved.

4. Which regions still represent growth opportunities for Ritonavir?
Low-income countries with limited access to newer drugs maintain demand for cost-effective Ritonavir-based regimens.

5. How do regulatory trends impact Ritonavir’s future?
Bioequivalence policies and patent challenges favor generics, further compressing branded sales.

---

References

[1] World Health Organization. (2022). HIV/AIDS treatment guidelines. Retrieved from https://www.who.int/publications/i/item/9789240031596

[2] IMS Health. (2022). Global HIV pharmaceutical market report.

[3] U.S. Food and Drug Administration. (2022). Drug approvals and labeling database.

[4] AbbVie. (2023). Ritonavir product information.

[5] IMS Institute for Healthcare Informatics. (2018). The global opportunity in HIV therapy.